Protalix BioTherapeutics (PLX) Revenue (2016 - 2025)
Historic Revenue for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $17.9 million.
- Protalix BioTherapeutics' Revenue fell 60.14% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year increase of 3541.51%. This contributed to the annual value of $53.4 million for FY2024, which is 1846.73% down from last year.
- Per Protalix BioTherapeutics' latest filing, its Revenue stood at $17.9 million for Q3 2025, which was down 60.14% from $15.7 million recorded in Q2 2025.
- In the past 5 years, Protalix BioTherapeutics' Revenue registered a high of $35.1 million during Q2 2023, and its lowest value of $3.7 million during Q1 2024.
- In the last 5 years, Protalix BioTherapeutics' Revenue had a median value of $11.3 million in 2021 and averaged $13.1 million.
- In the last 5 years, Protalix BioTherapeutics' Revenue skyrocketed by 30071.98% in 2023 and then tumbled by 6158.52% in 2024.
- Protalix BioTherapeutics' Revenue (Quarter) stood at $8.5 million in 2021, then grew by 0.8% to $8.6 million in 2022, then rose by 21.69% to $10.5 million in 2023, then surged by 73.74% to $18.2 million in 2024, then dropped by 2.01% to $17.9 million in 2025.
- Its Revenue was $17.9 million in Q3 2025, compared to $15.7 million in Q2 2025 and $10.1 million in Q1 2025.